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Péter Tamáska,14 Piroska Pettendi,15
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Summary
The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has revolutionised
the therapeutic landscape of chronic lymphocytic leukaemia (CLL). Acquired
mutations emerging at position C481 in the BTK tyrosine kinase domain are
the predominant genetic alterations associated with secondary ibrutinib
resistance. To assess the correlation between disease progression, and the
emergence and temporal dynamics of the most common resistance mutation
BTKC481S, sensitive (104) time-resolved screening was performed in 83
relapsed/refractory CLL patients during single-agent ibrutinib treatment.
With a median follow-up time of 40 months, BTKC481S was detected in
482% (40/83) of the patients, with 800% (32/40) of them showing disease
progression during the examined period. In these 32 cases, representing
727% (32/44) of all patients experiencing relapse, emergence of the
BTKC481S mutation preceded the symptoms of clinical relapse with a median
of nine months. Subsequent Bcl-2 inhibition therapy applied in 28/32
patients harbouring BTKC481S and progressing on ibrutinib conferred clinical
and molecular remission across the patients. Our study demonstrates the
clinical value of sensitive BTKC481S monitoring with the largest longitudi-
nally analysed real-world patient cohort reported to date and validates the
feasibility of an early prediction of relapse in the majority of ibrutinib-trea-
ted relapsed/refractory CLL patients experiencing disease progression.
Keywords: chronic lymphocytic leukemia, CLL, ibrutinib, treatment resis-
tance, molecular monitoring.
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Introduction
Chronic lymphocytic leukaemia (CLL) is characterised by
significant clinical heterogeneity coupled with a diverse geno-
mic, epigenomic and transcriptomic background.1 Recurrent
molecular and cytogenetic abnormalities have been identified
as underlying mechanisms for adverse disease course leading
to relapsed/treatment refractory (R/R) CLL. High-risk genetic
features such as complex karyotype, deletions of chromoso-
mal regions 11q (ATM) and 17p (TP53), TP53 gene muta-
tions as well as unmutated immunoglobulin heavy chain
variable (IGHV) gene status are commonly associated with
refractoriness to standard chemo-immunotherapies, early
relapse and inferior survival.2–4
Clinical management of patients with R/R CLL or with
treatment-naive CLL harbouring high-risk genetic features
has been revolutionized by the irreversible Bruton’s tyrosine
kinase (BTK) inhibitor ibrutinib which confers remarkable
response rates both in first-line and in previously treated
patient cohorts.5–9 Although clinical trials and the analyses of
real-world patient cohorts have shown a survival advantage
with ibrutinib over standard therapies,6,7,10–13 durable remis-
sion is eventually followed by either Richter’s transformation
or progressive CLL in a subset of the patients. While Rich-
ter’s transformation tends to occur during the first or second
year of ibrutinib treatment and its cumulative incidence
shows a plateau after the third year, CLL progression
emerges later, typically after a 12–15-month period of BTK
inhibition with events regularly occurring during the third,
fourth and fifth years after therapy initiation.13–16 Since ibru-
tinib failure confers poor survival, early detection of resis-
tance could provide clinically relevant information,
potentially optimising the transition of affected patients to
alternative treatment strategies with ideal timing during the
disease course.
CLL progression on ibrutinib is strongly associated with
acquired mutations emerging in BTK at the binding site of
ibrutinib and/or in the phospholipase Cc2 (PLCG2) gene
encoding the protein directly downstream of BTK in the
BCR signalling pathway.15–19 Indeed, while less than half of
the patients undergoing Richter’s transformation harbour
detectable BTK and PLCG2 mutations, these aberrations can
be observed in the vast majority (>80%) of patients experi-
encing progressive CLL.15,20,21 BTKC481S is by far the most
common resistance-associated mutation which, by disrupting
the covalent binding between BTK and ibrutinib, renders
ibrutinib a reversible inhibitor with decreased BTK binding
affinity.17,22 Although in the presence of the BTKC481S muta-
tion, ibrutinib still allows for some level of disease control
via its residual competitive binding, alternative single-agent
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or combined targeted therapy options should be considered
for patients harbouring this alteration in order to prevent or
overcome a potential relapse.23
In this study, we assessed the feasibility and clinical value
of sensitive longitudinal screening for BTKC481S mutation in
a real-world cohort of R/R CLL patients receiving single-
agent ibrutinib treatment. Our results provide an insight into
the temporal dynamics of this resistance mutation and will
expectedly have implications for the molecular monitoring of
ibrutinib therapy which may allow for the early identification




Peripheral blood samples were collected from 83 R/R CLL
patients (49 males and 34 females; median age at diagnosis:
57 years, range: 26–85 years) treated with ibrutinib in 13 Hun-
garian oncohaematological centres. This cohort comprised a
subset of 126 CLL patients who had been investigated in the
framework of the Hungarian Ibrutinib Resistance Analysis Ini-
tiative to date. Selected patients received ibrutinib in a daily
dose of 420 mg as a single-agent therapy for a minimum of
13 months (median 36 months, range: 13–68 months) and
represented a pretreated cohort with a median of two lines
(range: 1–6) of prior therapy. Clinical characteristics are sum-
marised in Table SI. The median follow-up time was
40 months (range: 13–69 months) with <10% of the samples
collected retrospectively and over 90% prospectively during
the study period. Considering patients progressing on ibruti-
nib, specimens obtained during ibrutinib treatment prior to
the first clinical signs of relapse were available in 568% (25/
44) of the cases, while the first follow-up sample of 19 patients
was received at the time of CLL progression. Follow-up sam-
ples of patients harbouring BTKC481S and/or progressing on
ibrutinib were received with a median interval of four months
(range: 1–11 months) allowing for a real-life time-resolved
monitoring of the resistance mutation. Peripheral blood
mononuclear cells (PBMC) were isolated by density gradient
centrifugation and the leukaemic cell purity was assessed by
flow cytometry using CD5/CD19/CD45 immunophenotypic
markers. After DNA extraction, IGHV mutation status and
TP53 mutations were analysed according to the most recent
European Research Initiative on CLL (ERIC) recommenda-
tions.24,25 Chromosomal abnormalities, including deletions of
11q, 13q and 17p as well as trisomy of chromosome 12, were
screened by interphase fluorescence in situ hybridisation
(FISH) using dual-colour Vysis probe sets (Abbott Molecular,
IL, USA). PBMCs from five healthy volunteers were used as
negative controls. Written informed consent was obtained
from all participants, the study was approved by the Hungar-
ian Medical Research Council (ID: 45371-2/2016/EKU) and it
was conducted in accordance with the Declaration of Helsinki.
Droplet digital PCR
Screening and quantitative assessment of the BTKC481S resis-
tance mutation was performed by droplet digital polymerase
chain reaction (ddPCR; Bio-Rad Laboratories, CA, USA)
using a custom assay that we previously designed for the dis-
criminative analysis of mutant and wild-type alleles.26 All
reactions were carried out according to the manufacturer’s
recommendations using 100 ng of input DNA. The allelic
burden of the mutation was defined as the fractional abun-
dance (FA) calculated from the ratio of the number of
mutant DNA molecules (a) and the total number of mutant
(a) plus wild-type (b) DNA molecules detected: FA = a/
(a + b). FA values were normalised to the CLL cell fraction
measured by flow cytometry. Quantitative reliability of the
assay was determined with linearity measurements using
dilution series and the sensitivity of the ddPCR analysis was
assessed for each sample. The lower limit of the quantitative
range could ubiquitously be determined as 001% FA.
Ultra-deep next-generation sequencing
Targeted next-generation sequencing (NGS) was performed on
follow-up samples of patients harbouring the wild-type
BTKC481 allele and progressing on ibrutinib using a QIAseq
Targeted DNA Custom Panel (Qiagen, Hilden, Germany) cov-
ering three genes (BTK, PLCG2 and TP53) relevant to ibrutinib
therapy and resistance. Libraries were prepared according to
the manufacturer’s recommendations and sequenced on a
MiSeq platform (Illumina, San Diego, CA, USA) with 150 bp
paired-end configuration. Data processing and analysis were
performed with the smCounter2 workflow utilising unique
molecular identifier-based variant calling which facilitates the
highly accurate detection of low-frequency variants.27 Variants
were annotated using the dbSNP, COSMIC, ClinVar, SnpSift
and SnpEff databases as well as the most recent versions of the
TP53-specific IARC/Seshat databases.28,29 Reported variant
allele frequencies (VAF) were normalised by considering the
ratio of CLL cells in the sample.
Statistics
GraphPad Prism 9.1.0 (GraphPad Software, San Diego, CA,
USA) was used for calculating median values and confidence
intervals, as well as for analysing the cumulative incidence of
disease progression in patients harbouring the BTKC481S
resistance mutation. The Mantel–Byar estimate of progres-
sion-free survival in patients with or without detectable
BTKC481S mutation was calculated by R version 4.0.2 (R
Foundation for Statistical Computing, Vienna, Austria).30
Results
Molecular and cytogenetic features considered as indepen-
dent prognostic markers in CLL were screened as part of the
Molecular Monitoring in Ibrutinib-Treated R/R CLL
ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd. British Journal of Haematology, 2021, 194, 355–364
357
diagnostic characterisation (Table SI). TP53 mutation status
revealed by ultra-deep NGS and del(17p) status analysed by
FISH were available in 75/83 and 81/83 cases, respectively.
Patients with del(17p) and/or TP53 mutation(s) represented
506% (42/83) of the study cohort. Further cytogenetic
abnormalities including del(11q), del(13q) and trisomy 12
were identified with a frequency of 157%, 265% and 120%,
respectively. IGHV mutation status was available for 79
patients with 873% of them carrying an unmutated IGHV
gene configuration (IGHV-U). High-risk genetic features
associated with adverse prognosis were observed in 892%
(74/83) of the patients, which together with failures on previ-
ous treatment lines is an indicator that our study group ade-
quately represented a real-world R/R CLL cohort with
patients typically selected for ibrutinib therapy.
Ultra-sensitive screening for the BTKC481S resistance
mutation
Retrospective and prospective screening for the ibrutinib
resistance-associated BTKC481S mutation was performed on a
total of 305 samples using a highly sensitive (104), locus-
specific ddPCR assay. With a median follow-up time of
40 months (range: 13–69 months), BTKC481S was detected in
482% (40/83) of the patients (Table SII) with 800% (32/40)
of them experiencing relapse or disease progression during
the examined period. These 32 cases represented 727% (32/
44) of all patients showing signs of clinical disease progres-
sion. The median FA value at the time of CLL progression
was 1066% (range: 001–9000%; 95% CI: 30–230%). Rich-
ter’s transformation was not observed among the 40
BTKC481S-positive patients.
Time-resolved monitoring of the BTKC481S mutation
The 32 patients harbouring detectable BTKC481S mutation
and experiencing secondary ibrutinib resistance underwent
disease progression after a median of 38 months (range: 13–
65 months; 95% CI: 320–440 months) of ibrutinib therapy.
In 19 patients with samples obtained prior to the progres-
sion, emergence of the resistance mutation preceded the
ibrutinib failure with a median of nine months (range: 0–
28 months; 95% CI: 30–120 months) as shown in Figs 1
and 2. Cumulative incidence of disease progression in
patients harbouring the BTKC481S resistance mutation and
having preprogression samples available for monitoring is
shown in Fig 3A. Median FA values of BTKC481S at the time
of the first detection versus at the time of disease progression
were 0385% vs 1066%, demonstrating a median 28-fold
increase in the allelic burden of the resistance mutation
(Fig 3B). The Mantle–Byar test was used for analysing CLL
progression on ibrutinib with all patients starting in the
BTKC481S-negative group and being transferred to the
BTKC481S-positive group upon first detection of the muta-
tion. A significantly inferior progression-free survival rate
was observed among patients acquiring detectable BTKC481S
mutation (P < 000001; Figure S1).
Management of secondary ibrutinib resistance in patients
with BTKC481S
Due to secondary ibrutinib resistance and disease progres-
sion, 875% (28/32) of the patients harbouring BTKC481S
have discontinued ibrutinib treatment. Subsequent BCL2
inhibitor venetoclax therapy administered to all these
patients resulted in clinical remission and elimination of the
BTKC481S mutant CLL subclones within a median of three
months (range: 2–7 months) across the cases. Despite the
remarkable and durable decrease in the abundance of the
mutations (Fig 4A), eight patients experienced disease pro-
gression and developed secondary venetoclax resistance dur-
ing the follow-up period (Fig 4B). Six out of these eight
patients have succumbed to their disease without receiving
any further treatment, while two patients are still alive to
date with one of them undergoing haematopoietic stem cell
transplantation and the other patient receiving salvage
chemo-immunotherapy.
Patients harbouring the BTKC481S mutation with no
signs of disease progression
The BTKC481S mutation was detected in eight patients with
no clinical evidence of relapse or disease progression during
the examined period (Figure S2). These patients, representing
200% of all patients harbouring BTKC481S (8/40), have con-
tinued ibrutinib therapy and were regularly monitored by
ddPCR. At the latest follow-up timepoints, the median FA
value of the resistance mutation was 069% (range: 0–20%)
after a median of 43 months (range: 23–68 months) of ibru-
tinib therapy. Interestingly, the emergence of BTKC481S was
later followed by the complete elimination of the acquired
mutation in three cases. Quantitative ddPCR analysis of
sequential samples obtained from the remaining five patients
revealed an increasing FA of the BTKC481S resistance muta-
tion, highlighting the significance of monitoring these
patients for signs of an impending relapse. Two patients
Fig 1. Treatment timeline of 19 patients with relapsed/treatment refractory (R/R) chronic lymphocytic leukaemia (CLL) harbouring the BTKC481S
ibrutinib resistance mutation and experiencing relapse or disease progression during the study period. Blue wedges denote the timepoint of the
first detection of BTKC481S with red wedges indicating the first clinical observation of disease progression. Emergence of the resistance mutation
was detectable with a median of nine months (range: 0–28 months) prior to the first clinical signs of CLL progression as indicated by the red
bars. Venetoclax therapy was administered in 895% (17/19) of the cases as represented by the yellow bars on each timeline.
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harbouring the resistance mutation but not experiencing dis-
ease progression died from reasons not related to CLL during
the follow-up period, with last measured BTKC481S FA values
of 008% and 191%, respectively (Figure S2).
Secondary ibrutinib resistance in patients with wild-type
BTKC481
Twelve patients progressing on ibrutinib carried wild-type
BTKC481 as assessed by ddPCR. This group, representing
273% of the patients experiencing relapse (12/44), showed
the first clinical signs of progression after a median of
26 months (range: 13–56 months) of ibrutinib therapy. As
an attempt to unveil alternative genomic alterations leading
to ibrutinib resistance, targeted ultra-deep sequencing cover-
ing all coding regions of the BTK, PLCG2 and TP53 genes
with a median depth of 4 1339 (range: 3 390–13 8569) was
performed on these patients’ samples obtained within a med-
ian of 15 months (range: 0–7 months) of the first clinical
signs of disease progression. Ultra-deep NGS uncovered a
novel PLCG2 mutation in the TIM (X-box) domain of the
PLCG2 protein in Patient #75, with no further resistance
Fig 2. Temporal dynamics of the BTKC481S resistance mutation in two relapsed/treatment refractory (R/R) chronic lymphocytic leukaemia (CLL)
patients treated with ibrutinib. (A) In Patient #13, BTKC481S was first detected after 27 months of ibrutinib therapy with a fractional abundance
(FA) value of 007%. Emergence of the resistance mutation predated the first clinical signs of disease progression by 25 months. In the last sam-
ple obtained two months after the onset of disease progression, BTKC481S was detected with an FA of 167%, representing a 239-fold temporal
increase in the allelic burden of the mutation. (B) Patient #35 experienced disease progression after 65 months of ibrutinib therapy. The BTKC481S
mutation was first detected with a FA of 002% after 37 months of ibrutinib therapy, hence its emergence preceded the first clinical signs of pro-
gression by 28 months. The resistance mutation with gradually increasing allelic burden was detectable in all samples received during the study
period. In the latest sample obtained two months after the first signs of clinical disease progression, BTKC481S was observed with a FA of 70%,
demonstrating a 3 500-fold increase in the allelic burden as compared to the first emergence of the resistance mutation.
Fig 3. Disease progression and fractional abundance of the mutation in patients harbouring BTKC481S. (A) Cumulative incidence of chronic lym-
phocytic leukaemia (CLL) progression after the first detection of BTKC481S. Emergence of the resistance mutation preceded the first clinical signs
of progression with a median of nine months (range: 0–28 months) in patients experiencing relapse. (B) Fractional abundance (FA) of BTKC481S
in individual patients at the first detection of the mutation versus at the time of disease progression. FA values of BTKC481S showed an increasing
allelic burden ubiquitously across the patients, including 11 males and eight females experiencing CLL progression. Patients with FA values of
BTKC481S higher than 50% at the time of progression were all males.
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mutations affecting the BTK and/or PLCG2 genes in the
analysed patients. The identified PLCG2 p.D334G
(c.1001A>G) variant is a previously unreported finding in
ibrutinib-resistant R/R CLL; however, the aspartic acid to
glycine change at the D334 residue was already found to be
associated with Richter’s transformation by Maddocks et al.14
Somatic variants detected by ultra-deep NGS across the
patients having wild-type BTKC481 and progressing on ibruti-
nib are listed in Table SIII.
Discussion
Ibrutinib has changed the therapeutic landscape of R/R CLL
with high response rates and durable progression-free sur-
vival.8,9,11,13,31,32 Long-term outcomes have predominantly
been reported in the context of clinical trials while real-
world cohort results have started to emerge only
recently.21,26,33–35 Despite the induction of an efficient dis-
ease control in the vast majority of R/R CLL patients, ibruti-
nib tends to lose efficacy in a subset of the cases, eventually
leading to disease progression and relapse. Indeed, the num-
ber of cases acquiring secondary ibrutinib resistance is grad-
ually accumulating over time with CLL progression
emerging regularly in all patient cohorts from the second
year of treatment.15,17,36 Since patients with ibrutinib failure
have poor outcome without additional/alternative therapeu-
tic interventions, there is a high clinical interest in the early
prediction of CLL progression which could potentially be
achieved by screening for resistance mutations in longitudi-
nally collected samples.
In the framework of the nationwide Hungarian Ibrutinib
Resistance Analysis Initiative, we investigated the feasibility
and value of screening for the most common resistance
mutations in ibrutinib-treated R/R CLL patients using an
ultra-sensitive ddPCR method. Our patients represent the
largest real-world cohort reported to date in which BTKC481S
has been monitored longitudinally. The mutation was
detected in nearly half of the patients with 80% of them
showing disease progression during the examined period.
Although, we only analysed a single aberration, this approach
identified the underlying resistance mutation and provided
informative genetic data for molecular monitoring in nearly
73% of the patients undergoing clinical disease progression.
In patients with samples obtained prior to progression, emer-
gence of the resistance mutation predated the first clinical
signs of ibrutinib failure with a median of nine months and
in 79% (15/19) of these cases, BTKC481S was detectable at
least three months before relapse. Consequently, in the
majority (73% 9 79% = 57%) of our patients with informa-
tive follow-up, presence and increasing abundance of the
BTKC481S mutation proved to be an indicator of the impend-
ing ibrutinib failure well before the first clinical signs of dis-
ease progression.
These findings are in line with results of previous studies
performed by our group and others. For example, Woyach
et al. investigated 46 patients experiencing CLL progression in
four clinical trials and identified BTK and/or PLCG2 mutations
in 87% of the relapse samples. Retrospective analysis of match-
ing serial samples available for 20 of these patients revealed
that emergence of the detectable mutations preceded the time
Fig 4. Temporal dynamics of the BTKC481S mutation in two patients with relapsed/treatment refractory (R/R) chronic lymphocytic leukaemia
(CLL) receiving ibrutinib and subsequent BCL2 inhibitor venetoclax therapies. (A) In the serial samples of Patient #6, emergence of the BTKC481S
was detectable after 24 months of ibrutinib therapy with a FA of 027%, predating the first clinical signs of disease progression with 12 months.
In samples obtained during the ramping-up period of subsequent venetoclax treatment, a temporary increase of the BTKC481S allelic burden was
observed which was followed by a sharp decrease in the FA values of the mutation. CLL cells carrying the BTKC481S were eliminated by the BCL2
inhibitor therapy and the mutation was undetectable in the sample obtained during the sixth month of venetoclax treatment. The patient was still
alive at the latest follow-up timepoint and showed no clinical signs of disease progression. (B) Emergence of BTKC481S in Patient #3 was detected
after 26 months of ibrutinib treatment predating the first clinical signs of disease progression by 12 months. After ibrutinib failure, venetoclax
therapy was administered which resulted in a sharp decline in the allelic burden of the mutation. Despite the abrupt reduction of the FA values,
recurrence of BTKC481S was observed after five months of venetoclax treatment predating a second progression by five months. The patient devel-
oped venetoclax resistance with an increasing allelic burden of BTKC481S and succumbed to her disease five months after the first clinical signs of
venetoclax failure.
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of relapse with an estimated median of 93 months.15 Ahn
et al. analysed CLL patients harbouring TP53 defects and
receiving ibrutinib in a phase 2 clinical trial and detected
BTKC481 and/or PLCG2 mutations in 8/10 patients showing
CLL progression. Six out of the eight patients had detectable
mutations predating the clinical progression by eight
months.16 In a real-world cohort of CLL patients still being on
ibrutinib after at least three years of treatment, Quinquenel
et al. performed a ‘snapshot’ screening to determine the preva-
lence of resistance mutations and found that the presence of
the BTK mutation was significantly associated with subsequent
CLL progression.21 Serial samples were not investigated in that
study. In our previous preliminary project, BTK and PLCG2
mutations were backtracked in five patients, and were detect-
able on average 105 months before the occurrence of clinical
relapse.26 These studies together provide a growing body of
evidence that BTK and PLCG2 mutations, with BTKC481S being
the predominant alteration, are drivers of ibrutinib resistance
and can be important biomarker candidates for molecular dis-
ease monitoring in CLL patients receiving ibrutinib.
Nevertheless, the role of testing for mutations before and
during ibrutinib treatment is still an intensively studied
research area and our limited understanding of the back-
ground of resistance poses a number of significant biological
and technical challenges. (i) Not all mutation-positive
patients experience disease progression, although the propor-
tion of patients with stable disease will probably be decreas-
ing with longer follow-up times available in the future. (ii)
CLL cell populations can be heterogeneous, comprising mul-
tiple subclones with different BTK and PLCG2 mutations.
The interaction between these subclones and their relative
contribution to the clinical relapse is poorly understood.16,37
(iii) At least 40% of the patients progressing on ibrutinib
harbour resistance mutations in minor subclones with a
cumulative VAF of <30% or even <10%,37 and the abun-
dance of mutations in the peripheral blood does not always
correlate with disease progression. One possible aetiology of
this phenomenon is a compartment effect, i.e. the site-speci-
fic (e.g. lymph node) presence/dominance of individual
mutations conferring underrepresentation of the resistance-
associated markers in CLL cells circulating in the peripheral
blood.15,38 Previously, we and others demonstrated that anal-
ysis of circulating cell-free DNA in blood plasma could offer
a more sensitive minimally invasive screening approach in
such cases.38,39 Another plausible explanation for the low fre-
quency of BTK/PLCG2 mutations at the time of clinical
relapse is the ability of CLL cells harbouring resistance muta-
tions to promote resistance in non-mutated malignant cells.
Chen et al. performed co-culture experiments with MYD88-
mutated Waldenstr€om macroglobulinaemia and ABC diffuse
large B-cell lymphoma cell lines and observed that
BTKC481 mutation can confer a protective effect against ibru-
tinib on neighbouring BTK wild-type cells through a para-
crine mechanism.40 (iv) Finally, 20% of the patients showing
CLL progression on ibrutinib carry no detectable BTK or
PLCG2 resistance mutations.37 Several alternative genetic aber-
rations and non-genetic mechanisms such as transcriptional
and epigenetic changes as well as microenvironmental effects
have been described as potential contributors of resis-
tance;8,14,18,20,41,42 however, further functional and clinical
studies are needed to clarify their causative role and the extent
of their contribution. Careful consideration of the circum-
stances mentioned above will be essential to design an efficient
disease-monitoring strategy which allows for the reliable pre-
diction of an impending relapse in clinical diagnostics.
Significance of detecting ibrutinib resistance at an early
stage has been increasing with the growing number of alter-
native treatment options emerging on the horizon. Patients
with ibrutinib failure can be treated with agents targeting
alternative oncogenic pathways, such as PI3K-mTOR and
BCL2. In clinical trial and real-world settings, remarkable
efficacy has been achieved with venetoclax in patients pro-
gressing on ibrutinib and this BCL2 antagonist has also con-
ferred massive reduction of CLL cells resistant to BTK
inhibition in our cohort.43,44 Ongoing clinical trials are eval-
uating the efficacy of venetoclax in combination with ibruti-
nib to overcome or prevent ibrutinib resistance.45–47 Further
promising approaches to tackle resistance to current irre-
versible BTK inhibition strategies include the application of
SYK inhibitors, CAR-T cells, BTK degraders, as well as rever-
sible BTK inhibitors which seem to be effective against CLL
cells regardless of their C481 mutation status.48–51 Several
studies have been investigating the optimal sequence, combi-
nation and duration of the various targeted therapies that
have become available recently, and the results will expect-
edly influence the required structure and organisation of
future molecular monitoring strategies.
In summary, our study demonstrates the potential of ultra-
sensitive monitoring to robustly detect BTKC481S during ibruti-
nib treatment under real-world circumstances, with the vast
majority of mutation-positive patients undergoing CLL pro-
gression. Based on the presented data, screening even for this
single aberration only can greatly facilitate the early detection
of resistance in at least ~60% of the patients experiencing
relapse. The predictive value of the test will most likely be
increasing with longer follow-up times available in the future.
In this regard, establishment of a standardised international
monitoring framework with optimal sampling intervals, sam-
ple processing steps and assay design/selection will also be
essential. Simultaneous interrogation of additional genomic
loci recurrently affected during clonal evolution will certainly
be unavoidable, especially with the introduction of alternative
and combined treatment strategies mentioned above. NGS
analysis with a focused gene panel seems to be a plausible
method for the comprehensive screening of resistance muta-
tions but affordability, short turn-around time, wide accessi-
bility and high sensitivity fulfilled by our current approach
should also be considered as requirements for subsequent dis-
ease monitoring. Technical and organisational standardisation
coupled with our gradually expanding knowledge of resistance
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mechanisms will hopefully further improve the clinical man-
agement of R/R CLL patients receiving novel targeted thera-
pies.
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Fig S1. Time-resolved BTKC481S monitoring and clinical
outcome in ibrutinib-treated CLL patients. Mantel–Byar esti-
mate of progression-free survival from the first detection of
BTKC481S. Patients experiencing disease progression with
samples obtained prior to relapse and cases with no clinical
signs of progression were included in the analysis.
Fig S2. Treatment timeline of eight patients harbouring
the BTKC481S resistance mutation with no clinical evidence of
disease progression during the study period. In this cohort,
representing 20% (8/40) of the cases with BTKC481S, emer-
gence of the resistance mutation was detected after a median
of 28 months (range: 19–44 months) of ibrutinib therapy as
denoted by blue wedges. Blue FA values represent the allelic
burden of BTKC481S at the first detection of the resistance
mutation while black FA values denote the allelic burden at
the time of the last patient follow-up.
Table SI. Patient characteristics.
Table SII. Fractional abundance (FA) of the BTKC481S
mutation assessed by droplet digital polymerase chain reac-
tion (ddPCR) in ibrutinib-treated relapsed/treatment refrac-
tory (R/R) ) chronic lymphocytic leukaemia (CLL) patients.
Table SIII. Variants detected by ultra-deep next-genera-
tion sequencing of the BTK, PLCG2 and TP53 genes in the
samples of patients progressing on ibrutinib but not har-
bouring the BTKC481S resistance mutation.
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38. Kiss R, Alpar D, Gangó A, Nagy N, Eyupoglu E, Aczel D, et al. Spatial clo-
nal evolution leading to ibrutinib resistance and disease progression in
chronic lymphocytic leukemia. Haematologica. 2019;104(1):e38–e41.
39. Albitar A, Ma W, DeDios I, Estella J, Ahn I, Farooqui M, et al. Using high-
sensitivity sequencing for the detection of mutations in BTK and PLCgam-
ma2 genes in cellular and cell-free DNA and correlation with progression
in patients treated with BTK inhibitors. Oncotarget. 2017;8(11):17936–44.
40. Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, et al. BTK
(Cys481Ser) drives ibrutinib resistance via ERK1/2 and protects BTK(wild-
type) MYD88-mutated cells by a paracrine mechanism. Blood. 2018;131
(18):2047–59.
41. Maffei R, Fiorcari S, Martinelli S, Potenza L, Luppi M, Marasca R. Target-
ing neoplastic B cells and harnessing microenvironment: the "double face"
of ibrutinib and idelalisib. J Hematol Oncol. 2015;8:60.
42. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K,
et al. Clonal evolution in patients with chronic lymphocytic leukaemia
developing resistance to BTK inhibition. Nat Commun. 2016;7:11589.
43. Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al.
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib:
an interim analysis of a multicentre, open-label, phase 2 trial. Lancet
Oncol. 2018;19(1):65–75.
44. Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS,
et al. Real-world outcomes and management strategies for venetoclax-trea-
ted chronic lymphocytic leukemia patients in the United States. Haemato-
logica. 2018;103(9):1511–7.
45. Hillmen P, Rawstron AC, Brock K, Mu~noz-Vicente S, Yates FJ, Bishop R,
et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic
leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722–9.
46. ClinicalTrials.gov. Venetoclax and Ibrutinib in Treating in Participants
With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations.
NCT03513562: ClinicalTrials.gov; 2019. Available from: https://clinicaltria
ls.gov/ct2/show/NCT03513562.
47. ClinicalTrials.gov. Ibrutinib and Venetoclax in Treating Patients With
Chronic Lymphocytic Leukemia After Ibrutinib Resistance: NCT03943342:
ClinicalTrialsgov; 2019. Available from: https://ClinicalTrials.gov/show/
NCT03943342.
48. Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, et al.
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new
treatment strategy for ibrutinib-resistant CLL. Blood. 2018;132(10):1039–49.
49. Matio A, Flinn I, Pagel J, Brown J, Cheah C, Coombs C, et al. Results
from a first-in-human, proof-of-concept phase I trial in pretreated B-cell
malignancies for LOXO-305, a next-generation, highly selective, noncova-
lent BTK inhibitor [abstract]. Blood. 2019;134(Suppl 1):501.
50. Allan JN, Patel K, Mato AR, Wierda WG, Pinilla Ibarz J, Choi MY, et al.
Ongoing results of a phase 1b/2 dose-escalation and cohort-expansion
study of the selective, noncovalent, reversible Bruton’s tyrosine kinase
inhibitor, vecabrutinib, in B-Cell malignancies [abstract]. Blood. 2019;134
(Suppl 1):3041.
51. Woyach J, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, et al.
Final Results of Phase 1, Dose escalation study evaluating ARQ 531 in
patients with relapsed or refractory B-Cell lymphoid malignancies [ab-
stract]. Blood. 2019;134(Suppl 1):4298.
C. B€od€or et al.
364 ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd. British Journal of Haematology, 2021, 194, 355–364
